Trending...
- Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
CINCINNATI, April 19, 2023 ~ Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, has been granted clearance by the United States Food and Drug Administration (FDA) for its new Curian® Shiga Toxin assay. This assay joins Curian HpSA® and Curian Campy as Meridian expands its Curian diagnostic platform to maintain leadership in the gastrointestinal disease testing market.
Foodborne illness is a severe global public health problem that causes 48 million people to get sick yearly and 128,000 hospitalizations from common bacterial agents like Campylobacter and E. coli.1 In order to address this issue, Meridian is expanding its foodborne immunofluorescent testing capabilities beyond Campylobacter by adding Shiga toxin to the Curian platform.
The Curian Shiga Toxin assay is a rapid immunoassay for the detection and differentiation of Shiga toxin 1 and Shiga toxin 2. It is designed for use with the Curian analyzer and intended for use with cultures derived from human stool specimens to aid in diagnosing diseases caused by Shiga toxin-producing E. coli (STEC) infections, including non-O157 strains. The immunofluorescent technology of the Curian platform provides an objective, rapid Shiga toxin result with an unmatched clinical sensitivity of 100% (Stx1), 100% (Stx2), and specificity of 99.4% (Stx1), 99.5% (Stx2) in prospective samples. It also features a lower limit of detection than traditional rapid immunoassay testing, combined with LIS connectivity which helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually based lateral flow test results.
More on Ohio Pen
Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics said: "We are excited to continue the expansion of the Curian platform with this highly sensitive and specific assay. Curian now features the broadest menu of GI tests on an immunoassay analyzer." He added: "Curian Shiga Toxin has a market-leading three-step sample prep workflow and produces fast, objective results that can help laboratorians and clinicians provide an objective Shiga toxin diagnosis to get patients on the correct treatment and back on the road to wellness."
Meridian Bioscience's new Curian® Shiga Toxin assay is expected to help reduce foodborne illnesses worldwide by providing a more accurate diagnosis for patients suspected of having a STEC infection so they can receive timely treatment before complications arise.
Foodborne illness is a severe global public health problem that causes 48 million people to get sick yearly and 128,000 hospitalizations from common bacterial agents like Campylobacter and E. coli.1 In order to address this issue, Meridian is expanding its foodborne immunofluorescent testing capabilities beyond Campylobacter by adding Shiga toxin to the Curian platform.
The Curian Shiga Toxin assay is a rapid immunoassay for the detection and differentiation of Shiga toxin 1 and Shiga toxin 2. It is designed for use with the Curian analyzer and intended for use with cultures derived from human stool specimens to aid in diagnosing diseases caused by Shiga toxin-producing E. coli (STEC) infections, including non-O157 strains. The immunofluorescent technology of the Curian platform provides an objective, rapid Shiga toxin result with an unmatched clinical sensitivity of 100% (Stx1), 100% (Stx2), and specificity of 99.4% (Stx1), 99.5% (Stx2) in prospective samples. It also features a lower limit of detection than traditional rapid immunoassay testing, combined with LIS connectivity which helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually based lateral flow test results.
More on Ohio Pen
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- Festo Features Multi-Axis Positioning Systems at Automate
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics said: "We are excited to continue the expansion of the Curian platform with this highly sensitive and specific assay. Curian now features the broadest menu of GI tests on an immunoassay analyzer." He added: "Curian Shiga Toxin has a market-leading three-step sample prep workflow and produces fast, objective results that can help laboratorians and clinicians provide an objective Shiga toxin diagnosis to get patients on the correct treatment and back on the road to wellness."
Meridian Bioscience's new Curian® Shiga Toxin assay is expected to help reduce foodborne illnesses worldwide by providing a more accurate diagnosis for patients suspected of having a STEC infection so they can receive timely treatment before complications arise.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI
- Sanders® Celebrates 150 Years with an Immersive NYC Experience, Food Truck Tour, and Exciting New White Chocolate Caramel Creations
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
- ABM for Good™ Launches First Project with Build Change
- ProfiSignal 20 Update Provides Significant Features
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)